Fixing Generic Reimbursement and Shortages: A Prescription for Stability and Access is the kind of topic that looks straightforward until it collides with the speed, ambiguity, and competing demands of clinical documentation, payer communication, supervision records, and leadership review. In Fixing Generic Reimbursement and Shortages: A Prescription for Stability and Access, for this course, the practical stakes show up in service continuity, accurate reporting, and defensible clinical decisions, not in abstract discussion alone.
Provider: BehaviorLive — via AVBCC
Take This Course →Including ethics, supervision, and topics like this one. New live CEU every Wednesday.
Join Free →Imagine a healthcare system where generic drugs are consistently available and affordable, benefiting both patients and providers. Yet, the current generic reimbursement model is fundamentally flawed, leading to chronic shortages and financial strain on manufacturers and healthcare providers. With reimbursement rates often below the cost of production, manufacturers struggle to maintain profitability, while providers face unsustainable costs for administering these therapies. This critical panel will tackle the pressing issue of generic drug reimbursement, focusing on actionable solutions to ensure a stable supply chain, equitable access to essential medications, and sustainable business models for all stakeholders. Join us as we explore innovative strategies to transform the generic drug landscape, ensuring that everyone—patients, providers, and manufacturers—wins.
| Certification Body | Credits | Type |
|---|---|---|
| BACB | 1 | General |
Barry Brooks is a physician shareholder who specializes in medical oncology and hematology working in Texas Oncology, the world's largest community oncology practice with 430 oncologists. Dr. Brooks is a founding member of Texas Oncology and currently serves as chairman of P&T for TOPA. Texas Oncology is part of The US Oncology Network and Dr. Brooks has served as its physician lead on The US Oncology Network Drug Contracting Committee since 2005. He has been a member of The US Oncology Network P&T Executive Committee since 2005 and served as Chairman of P&T from 2011 until 2019. He currently serves as Medical Director for Oral Oncolytics for McKesson Specialty Health and The US Oncology Network. Dr. Brooks was a founding member of The US Oncology Network’s Pathways Task Force, which was the originator of putting clinical pathways into everyday use in oncology practice. He is a member of the National Community Oncology Dispensing Association (NCODA) Executive Committee and is an active member of the US Oncology and Texas Oncology legislative political action committees where he advocates for the interests of community oncology. He is also a member of the Community Oncology Alliance (COA). Dr. Brooks still sees patients about half time and spends the rest of his time talking to drug manufacturers, providers, and pharmacists about all aspects of oncology medications. When he is not working, Dr. Brooks can be found on his golf course or in the water with a fly rod in his hand.
Dig into the research behind this topic — plain-English summaries written for BCBAs.
225 research articles with practitioner takeaways
171 research articles with practitioner takeaways
142 research articles with practitioner takeaways
You earn CEUs from a dozen different places. Upload any certificate — from here, your employer, conferences, wherever — and always know exactly where you stand. Learning, Ethics, Supervision, all handled.
No credit card required. Cancel anytime.
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.